Arctigenin
Based on 17 publication(s) in Google Scholar
Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions.
For research use only. We do not sell to patients.
- Purity: 99.63%
- CAS No.: 7770-78-7
- Formula: C21H24O6
- Molecular Weight:372.41
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Arctigenin
More- Pharmacol Res. 2020 May;155:104751. [Abstract]
- Pharmacol Res. 2020 May;155:104721. [Abstract]
- J Pharm Anal. 2026 Mar 10.
- Life Sci. 2020 Sep 1;256:117983. [Abstract]
- Eur J Pharmacol. 2026 Mar 28:1019:178694. [Abstract]
- Eur J Pharmacol. 2022 Mar 15:919:174808. [Abstract]
- RSC Adv. 2026 May 26;16(31):28583-28591. [Abstract]
- Mol Neurobiol. 2026 Feb 14;63(1):438. [Abstract]
- Biomedicines. 2022 Oct 31;10(11):2760. [Abstract]
- Heliyon. 2023 May 25;9(6):e16683. [Abstract]
- Toxicol Appl Pharmacol. 2025 Aug 11:504:117510. [Abstract]
- Chem Biol Drug Des. 2026 Apr;107(4):e70300. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Biochem Biophys Res Commun. 2024 May 28:710:149895. [Abstract]
- Res Sq. 2025 Aug 22.
- SSRN. 2025 Jul 8.
- Research Square Preprint. 2021 Aug.
-
WB
-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
-
In Vivo Efficacy Study
-
RT-PCR
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>50 μM
Compound: ATG
|
Cytotoxicity against human A549 cells after 4 days under normal conditions by MTT assay
Cytotoxicity against human A549 cells after 4 days under normal conditions by MTT assay
|
[PMID: 25571795] |
| A549 | IC50 |
6.57 μM
Compound: ATG
|
Cytotoxicity against human A549 cells after 4 days under glucose-starved conditions by MTT assay
Cytotoxicity against human A549 cells after 4 days under glucose-starved conditions by MTT assay
|
[PMID: 25571795] |
| A549 | IC50 |
0.8 μg/mL
Compound: 9
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay
|
[PMID: 32223924] |
| H9 | EC50 |
0.42 μM
Compound: 27
|
Antiviral activity against HIV1 infected in human H9 cells assessed inhibition of viral replication
Antiviral activity against HIV1 infected in human H9 cells assessed inhibition of viral replication
|
[PMID: 9834179] |
| HeLa | EC50 |
>100 μM
Compound: 1
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by WST-8 assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by WST-8 assay
|
[PMID: 28754364] |
| HeLa | IC50 |
572.7 μM
Compound: Arctigenin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
|
[PMID: 30237124] |
| HepG2 | IC50 |
2.8 μg/mL
Compound: 9
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay
|
[PMID: 32223924] |
| HL-60 | EC50 |
12 μM
Compound: 1
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by WST-8 assay
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by WST-8 assay
|
[PMID: 28754364] |
| HL-60 | IC50 |
13 μM
Compound: 1
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability
Cytotoxicity against human HL60 cells assessed as reduction in cell viability
|
[PMID: 32359854] |
| MDA-MB-231 | IC50 |
1.1 μg/mL
Compound: 9
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay
|
[PMID: 32223924] |
| MRC5 | CC50 |
76 μM
Compound: 7
|
Cytotoxicity against MRC5 cells
Cytotoxicity against MRC5 cells
|
[PMID: 17239594] |
| MRC5 | IC50 |
2.1 μM
Compound: 7
|
Antiviral activity against HCMV in MRC5 cells by plaque reduction assay
Antiviral activity against HCMV in MRC5 cells by plaque reduction assay
|
[PMID: 17239594] |
| PANC-1 | IC50 |
2.2 μM
Compound: Arctigenin
|
Growth inhibition of human PANC1 cells in nutrient-deprived medium incubated for 24 hrs by MTT assay
Growth inhibition of human PANC1 cells in nutrient-deprived medium incubated for 24 hrs by MTT assay
|
[PMID: 30878830] |
| RAW264.7 | IC50 |
10 nM
Compound: K00231, Arctigenin
|
Inhibition of LPS induced iNOS induced expression in mouse Raw264.7cells
Inhibition of LPS induced iNOS induced expression in mouse Raw264.7cells
|
[PMID: 18077363] |
| RAW264.7 | IC50 |
0.26 mM
Compound: 10
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs
|
[PMID: 18986199] |
| RAW264.7 | IC50 |
0.26 μM/mL
Compound: 10
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs
|
[PMID: 18986199] |
| Sf9 | IC50 |
6.7 μM
Compound: 1
|
Cytotoxicity against Spodoptera frugiperda Sf9 cells assessed as reduction in cell viability
Cytotoxicity against Spodoptera frugiperda Sf9 cells assessed as reduction in cell viability
|
[PMID: 32359854] |
Arctigenin (0.01-1 μg/mL; 0.5-24 h) shows preferential cytotoxicity against the PANC-1 cell line under nutrient-deprived conditions in a concentration- and time-dependent manner[1].
Arctigenin (0.01-1 μg/mL; 0.5-24 h) inhibits the survival of various cancer cell lines (ASPC-1, BXPC-3, Alexander, and PSN-1 cells) under nutrient-deprived conditions[1].
Arctigenin (0.1-1 μg/mL; 24 h) completely inhibits Akt phosphorylation stimulated by glucose deprivation in PANC-1 cells[1].
Arctigenin (5-25 μM) shows potent in vitro antiviral activities (IC50=2.9 μM) against influenza A virus[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Arctigenin (10 mg/kg; i.p. daily for 30 days) relieves experimental autoimmune encephalomyelitis (EAE) symptoms of mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female SPF/VAF BALB/cAn Ncrj-nu/nu mice were injected with PANC-1 cells[1]
-
Dosage:250 μg/mL, 0.2 mL
-
Administration:I.p. 6 times a week for 9 weeks
-
Result:Reduced the tumor weight and volume.
No significant body weight loss was recognized.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 7770-78-7
-
Appearance Solid
-
Molecular Weight 372.41
-
Formula C21H24O6
-
Color White to off-white
-
SMILES
O=C1OC[C@H](CC2=CC=C(OC)C(OC)=C2)[C@H]1CC3=CC=C(O)C(OC)=C3
-
Synonyms
(-)-Arctigenin
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 1 year -20°C 6 months
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Pharmacol Res
Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]2020 May;155:104751. PMID: 32151678 -
Pharmacol Res
2020 May;155:104721. PMID: 32097750
Arctigenin purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2020 May;155:104721. [Abstract]
The Western blotting results show that incubating LA795 cells with 100 μM Arctigenin (24 h) led to a decrease in phospho-MEK1/2, phospho-ERK1/2 and cyclin D1 expression (n = 3).
Arctigenin purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2020 May;155:104721. [Abstract]
Arctigenin (10-200 μM; 24 h) inhibited LA795 cell proliferation by inhibiting TMEM16A. (A), (B), (C) Inhibitory effect of arctigenin to the proliferation of LA795, HeLa and HEK293 cells with different concentrations (n = 8; ** means the P value was less than 0.01 compared with 0 μM group). (D) Inhibitory effect of NC shRNA, TMEM16A shRNA and shRNA added with 200 μM arctigenin to the proliferation of LA795 cells (n = 8; ** means the P value was less than 0.01 compared with control group).
Arctigenin purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2020 May;155:104721. [Abstract]
Migration of LA795 cells in the presence of 0, 10, 20, 50, 100, and 200 μM Arctigenin assessed by wound healing assay.
Arctigenin purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2020 May;155:104721. [Abstract]
The tumor volume growth curve in different groups (n = 6). Arctigenin (14.37 mg/kg; s.c.; once every two days for a total of 9 doses) inhibited the growth of lung adenocarcinomas in xenograft model mice.
-
-
Life Sci
Arctigenin inhibits proliferation of ER-positive breast cancer cells through cell cycle arrest mediated by GSK3-dependent cyclin D1 degradation. [Abstract]2020 Sep 1;256:117983. PMID: 32565252
Arctigenin purchased from MedChemExpress. Usage Cited in: Life Sci. 2020 Sep 1;256:117983. [Abstract]
The indicated cell lines are treated with 5 μM Arc (Arctigenin) for 10 h and then harvested for extraction of total cellular RNA and subsequent qRT-PCR.
-
Eur J Pharmacol
A novel arctigenin derivative attenuates nonalcoholic fatty liver disease by activating adiponectin receptor 1-mediated AMPK signaling pathway. [Abstract]2026 Mar 28:1019:178694. PMID: 41765270 -
Eur J Pharmacol
Arctigenin inhibits abnormal germinal center reactions and attenuates murine lupus by inhibiting IFN-I pathway. [Abstract]2022 Mar 15:919:174808. PMID: 35151645 -
RSC Adv
A Natural product-based composite nanozyme synergistically induces ferroptosis for lung cancer therapy. [Abstract]2026 May 26;16(31):28583-28591. PMID: 42211359 -
Mol Neurobiol
ARC-18 Alleviates Alzheimer-like Pathology and Cognitive Deficits via AdipoR1-Mediated Activation of Autophagy and Modulation of APP Processing. [Abstract]2026 Feb 14;63(1):438. PMID: 41689616 -
Biomedicines
Arctigenin Attenuates Vascular Inflammation Induced by High Salt through TMEM16A/ESM1/VCAM-1 Pathway. [Abstract]2022 Oct 31;10(11):2760. PMID: 36359280 -
Heliyon
Arctigenin hinders the invasion and metastasis of cervical cancer cells via the FAK/paxillin pathway. [Abstract]2023 May 25;9(6):e16683. PMID: 37292259 -
Toxicol Appl Pharmacol
Arctigenin relieves inflammation and remodels the nasal epithelial barrier function in allergic rhinitis via the KLF5/BIRC3/NFκB axis. [Abstract]2025 Aug 11:504:117510. PMID: 40803538 -
Chem Biol Drug Des
Preliminary Study on the Mechanism of Arctigenin in Alleviating Osteoarthritis Pain by Suppressing Chondrocyte Pyroptosis: The Potential Role of the POU2F1/GRB10 Axis. [Abstract]2026 Apr;107(4):e70300. PMID: 42041039 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Biochem Biophys Res Commun
Non-cytotoxic nanomolar concentration of arctigenin protects neuronal cells from chemotherapy-induced ferroptosis by regulating SLC7A11-cystine-cysteine axis. [Abstract]2024 May 28:710:149895. PMID: 38593620 -
-
-
Solvent & Solubility
DMSO : 100 mg/mL (268.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Awale S, et, al. Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res. 2006 Feb 1;66(3):1751-7. [Content Brief]
[2]. Gao Q, et, al. Overview of the anti-inflammatory effects, pharmacokinetic properties and clinical efficacies of arctigenin and arctiin from Arctium lappa L. Acta Pharmacol Sin. 2018 May;39(5):787-801. [Content Brief]
[3]. Hayashi K, et, al. Therapeutic effect of arctiin and arctigenin in immunocompetent and immunocompromised mice infected with influenza A virus. Biol Pharm Bull. 2010;33(7):1199-205. [Content Brief]
[4]. Wei L, et, al. Arctigenin Exerts Neuroprotective Effect by Ameliorating Cortical Activities in Experimental Autoimmune Encephalomyelitis In Vivo. Front Immunol. 2021 Jul 19;12:691590. [Content Brief]
[5]. Maxwell T, et, al. Arctigenin inhibits the activation of the mTOR pathway, resulting in autophagic cell death and decreased ER expression in ER-positive human breast cancer cells. Int J Oncol. 2018 Apr;52(4):1339-1349. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6852 mL | 13.4261 mL | 26.8521 mL | 67.1303 mL |
| 5 mM | 0.5370 mL | 2.6852 mL | 5.3704 mL | 13.4261 mL | |
| 10 mM | 0.2685 mL | 1.3426 mL | 2.6852 mL | 6.7130 mL | |
| 15 mM | 0.1790 mL | 0.8951 mL | 1.7901 mL | 4.4754 mL | |
| 20 mM | 0.1343 mL | 0.6713 mL | 1.3426 mL | 3.3565 mL | |
| 25 mM | 0.1074 mL | 0.5370 mL | 1.0741 mL | 2.6852 mL | |
| 30 mM | 0.0895 mL | 0.4475 mL | 0.8951 mL | 2.2377 mL | |
| 40 mM | 0.0671 mL | 0.3357 mL | 0.6713 mL | 1.6783 mL | |
| 50 mM | 0.0537 mL | 0.2685 mL | 0.5370 mL | 1.3426 mL | |
| 60 mM | 0.0448 mL | 0.2238 mL | 0.4475 mL | 1.1188 mL | |
| 80 mM | 0.0336 mL | 0.1678 mL | 0.3357 mL | 0.8391 mL | |
| 100 mM | 0.0269 mL | 0.1343 mL | 0.2685 mL | 0.6713 mL |